Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2013/051443external-prioritypatent/WO2013124826A1/en
Application filed by Novartis AgfiledCriticalNovartis Ag
Publication of MA35894B1publicationCriticalpatent/MA35894B1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La présente invention concerne des composés de pyrimidine à substitution oxazolidine-2-one qui agissent en tant qu'inhibiteurs de la pi3k (phosphatidylinositol-3-kinase), ainsi que des compositions pharmaceutiques les comprenant, des procédés de fabrication et des utilisations associées pour le traitement d'affections, de maladies et de troubles dépendant de la pi3k.The present invention relates to oxazolidin-2-one substituted pyrimidine compounds which act as inhibitors of pi3k (phosphatidylinositol-3-kinase), as well as pharmaceutical compositions comprising them, methods of manufacture and associated uses for treatment of pediatric disorders, diseases and disorders.
MA37253A2012-02-242014-07-31
Oxazolidin-2-one compounds and uses thereof as pi3k inhibitors
MA35894B1
(en)
Derivatives of 3-substituted oestra-1,3,5 (10), 16-tetraene, processes for their preparation, pharmaceutical preparations containing them, and their use in the manufacture of medicaments
N- [4- (quinolin-4-yloxy) cyclohexyl (methyl)] (hetero) arylcarboxamides for use as androgen receptor antagonists, their production and their use as medicaments